Dorrapharma Showcases at CPHI Milan 2026, Driving Global Pharmaceutical Collaboration via Technology Platforms

发布时间： 2026-10-09 阅读：115次

分享

On October 6，CPHI Milan 2026 opened at Fiera Milano, Italy. The Dorrapharma business team presented at Booth 2A94, demonstrating the company’s integrated pharmaceutical service capacity spanning R&D, process development, compliance and delivery to global partners. The portfolio featured high-value small-molecule APIs, key materials for peptides and oligonucleotides, non-biological polymers, custom synthesis CDMO services and formulation licensing collaborations.

As the most influential event for the global pharma raw material and manufacturing supply chain, CPHI Milan 2026 gathered over 62,000 industry professionals and more than 2,400 exhibitors from 160+ countries and regions. It serves as a key platform to track trends in global pharmaceutical supply chains, innovative drug outsourcing and international partnerships.

【Technology Platforms on Display: End-to-End Capabilities from Molecule to Delivery】

Dorrapharma highlighted its core technology platforms at the exhibition:

• Flow chemistry: Enhances safety and scalability of high-risk reactions

• Enzyme catalysis: Enables green synthesis, optimizes process routes and cuts waste and production costs

• Peptide synthesis platform: Supports fragment and side-chain production for multiple peptide therapeutics

•Non-biologic polymer: Targeting therapeutic areas including hyperkalemia and hyperphosphatemia

Powered by these four core technology platforms, Dorrapharma supplies high-value APIs and CDMO services covering lab-scale research, pilot development and commercial manufacturing. All deliveries are backed by certifications from major regulatory authorities worldwide.

【Global Engagements: Productive Meetings with Clients across Europe, North America and Asia-Pacific】

Dorrapharma hosted intensive discussions with long-term European procurement partners, North American biotech innovators, Asia-Pacific formulation manufacturers and API distributors. Conversations focused on process optimization, impurity profiling, regulatory documentation, capacity scheduling, patent-expired products, and supply of peptide and oligonucleotide raw materials.

Following participation in CPHI Japan, CHEMSPEC Europe, CPHI China and BOS Basel, Dorrapharma once again took the stage at a leading global pharma exhibition. Leveraging its combined China-Europe team, the company translates its “fast response + localized service” for European and North American markets into tangible project wins.

【Formulation Business: Dual Engine for Global Expansion via “MAH + Licensing” 】

Beyond APIs and CDMO, Dorrapharma prioritized its formulation collaboration network in Milan:

• In-licensing promising innovative assets and high-quality established generic products

• Focusing on assets approved in Europe and the US with strong clinical value and favourable competitive landscape in China

• Building a two-way channel for international formulation partnerships and China market entry through “MAH + Licensing” model

Deep synergy between products and services is advancing Dorrapharma’s evolution into a value co-creator within the global pharmaceutical supply chain.

【Committed to Globalization: Bringing China’s Manufacturing Expertise to the World】

Over the past 15 years, Dorrapharma has built long-term stable partnerships with hundreds of clients across dozens of countries. Overseas customers account for more than 90% of its total client base. This achievement stems from sustained investment in global expansion: a business development centre in Switzerland and integrated China-Europe commercial and technical teams turn “localized responsiveness” into tangible communication efficiency and project execution for partners.

The company’s footprint stretches across established European markets and emerging Asia-Pacific regions, covering stable API supply and early-stage CDMO R&D partnerships. Its globalization strategy validates the enduring strength of the model combining China supply capacity with localized customer service, keeping Dorrapharma closely aligned with clients amid shifting global pharmaceutical industry dynamics.

Facing the new landscape of the global pharmaceutical industry, Dorrapharma remains committed to: building on technology platforms, adhering to rigorous quality and compliance standards, drawing support from flexible manufacturing capacity, to deliver more efficient, greener and predictable pharmaceutical R&D and supply solutions for partners worldwide.